In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More members will be enrolled with the discovered monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In Phase https://abbv-744-in-clinical-tria57902.blogripley.com/32674279/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy